Harris Erik 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Jun 21, 2023
Insider Transaction Report
Form 4
Harris Erik
EVP & Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-06-19$48.20/sh−305$14,701→ 57,281 total
Footnotes (3)
- [F1]Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
- [F2]Includes 242 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.
- [F3]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.